Mustang Bio Files 2024 Annual Report
Ticker: MBIO · Form: 10-K · Filed: Mar 28, 2025 · CIK: 1680048
Sentiment: neutral
Topics: 10-k, annual-report, financials, warrants
TL;DR
MBIO 2024 10-K is in. Financials and warrant details disclosed.
AI Summary
Mustang Bio, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in Worcester, MA, operates in the pharmaceutical preparations sector. Key financial data points and valuation inputs for warrants were disclosed, indicating a focus on their financial instruments and potential future share issuances.
Why It Matters
This filing provides a comprehensive overview of Mustang Bio's financial health and operational status for the past fiscal year, crucial for investors assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The filing contains detailed financial information, including disclosures about warrants, which can introduce complexity and potential dilution risks for shareholders.
Key Numbers
- 2200000 — Shares (Potential shares related to warrants or other financial instruments.)
- 0.02 — Share Price (Input for warrant valuation on 2024-10-25.)
- 0.02 — Risk-Free Interest Rate (Input for warrant valuation on 2024-10-25.)
- 0.02 — Price Volatility (Input for warrant valuation on 2024-10-25.)
- 0.02 — Expected Term (Input for warrant valuation on 2024-10-25.)
Key Players & Entities
- Mustang Bio, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- Worcester, MA (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 001-38191 (sec_file_number) — SEC File Number for Mustang Bio, Inc.
FAQ
What is the total number of shares outstanding as of December 31, 2024?
The provided snippet does not explicitly state the total number of outstanding shares. It mentions '2200000' which is likely related to warrant shares or a specific class of shares.
What were Mustang Bio's total revenues for the fiscal year ended December 31, 2024?
The provided snippet does not contain information on total revenues for the fiscal year ended December 31, 2024.
What is the company's cash and cash equivalents balance as of December 31, 2024?
The provided snippet does not disclose the company's cash and cash equivalents balance.
What are the specific terms and expiration dates of the Series B1 and Series B2 warrants mentioned?
The snippet indicates that valuation inputs for 'NewSeriesB2WarrantSharesMember' and 'NewSeriesB1WarrantSharesMember' were recorded on 2024-10-25, but does not detail the specific terms or expiration dates of these warrants.
What is the company's net income or loss for the fiscal year ended December 31, 2024?
The provided snippet does not include information regarding the company's net income or loss for the fiscal year ended December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding MUSTANG BIO, INC. (MBIO).